The federal agency authorized the use of the Eli Lilly & Co. weight loss drug for “treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.” In addition to the GLP-1 prescription, the FDA suggests that users reduce their calorie intake and increase their exercise.

The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to severe OSA in people with obesity.

Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration on Friday approved the weight loss drug Zepbound to treat obstructive sleep apnea. It is the first prescription medication approved to treat the common sleep disorder.

T he weight-loss drug Zepbound (tirzepatide) now has another major benefit: on Dec. 20, it became the first drug approved by the U.S. Food and Drug Administration (FDA) to treat obstructive sleep apnea.

Key Takeaways Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with sleep apnea and obesity, the drugmaker said after the bell Friday.Trials of the Lilly drug found that it helped reduce the number of breathing disruptions in an average night of sleep.

The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have obesity

The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in combination with diet and exercise.

The U.S. Food and Drug Administration (FDA) has approved the first prescription medication specifically for treating obstructive sleep apnea (OSA): the weight-loss drug Zepbound.

The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA announced today.